Literature DB >> 18207484

Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/- gammac -/- (RAG-hu) mice.

Bradford K Berges1, Sarah R Akkina, Joy M Folkvord, Elizabeth Connick, Ramesh Akkina.   

Abstract

Studies on HIV-1 mucosal transmission to evaluate early events in pathogenesis and the development of effective preventive/prophylactic methods have thus far been hampered by the lack of a suitable animal model susceptible to HIV-1 infection by either vaginal and/or rectal routes. In this regard, while primate-SIV/SHIV and cat-FIV models provided useful surrogate platforms to derive comparative data, these viruses are distinct and different from that of HIV-1. Therefore an optimal model that permits direct study of HIV-1 transmission via mucosal routes is highly desirable. The new generation of humanized NOD/SCID BLT, NOD/SCIDgammac(-/-), and Rag2(-/-)gammac(-/-) mouse models show great promise to achieve this goal. Here, we show that humanized Rag2(-/-)gammac(-/-) mice (RAG-hu) engrafted with CD34 hematopoietic progenitor cells harbor HIV-1-susceptible human cells in the rectal and vaginal mucosa and are susceptible to HIV-1 infection when exposed to cell-free HIV-1 either via vagina or rectum. Infection could be established without any prior hormonal conditioning or mucosal abrasion. Both R5 and X4 tropic viruses were capable of mucosal infection resulting in viremia and associated helper T cell depletion. There was systemic spread of the virus with infected cells detected in different organs including the intestinal mucosa. R5 virus was highly efficient in mucosal transmission by both routes whereas X4 virus was relatively less efficient in causing infection. HIV-1 infection of RAG-hu mice by vaginal and rectal routes as shown here represents the first in vivo model of HIV-1 transmission across intact mucosal barriers and as such may prove very useful for studying early events in HIV-1 pathogenesis in vivo, as well as the testing of microbicides, anti-HIV vaccines/therapeutics, and other novel strategies to prevent HIV-1 transmission.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18207484      PMCID: PMC3092740          DOI: 10.1016/j.virol.2007.11.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract.

Authors:  K B Collins; B K Patterson; G J Naus; D V Landers; P Gupta
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

Review 2.  Transmission, acute HIV-1 infection and the quest for strategies to prevent infection.

Authors:  Melissa Pope; Ashley T Haase
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

3.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

Review 4.  Human immunodeficiency virus infection of human cells transplanted to severe combined immunodeficient mice.

Authors:  D E Mosier
Journal:  Adv Immunol       Date:  1996       Impact factor: 3.543

Review 5.  The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS.

Authors:  B D Jamieson; G M Aldrovandi; J A Zack
Journal:  Semin Immunol       Date:  1996-08       Impact factor: 11.130

6.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

7.  Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus.

Authors:  C J Miller; N J Alexander; S Sutjipto; A A Lackner; A Gettie; A G Hendrickx; L J Lowenstine; M Jennings; P A Marx
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

8.  Dengue virus infection and immune response in humanized RAG2(-/-)gamma(c)(-/-) (RAG-hu) mice.

Authors:  Jes G Kuruvilla; Ryan M Troyer; Shamala Devi; Ramesh Akkina
Journal:  Virology       Date:  2007-08-16       Impact factor: 3.616

Review 9.  Transmission and immunopathogenesis of FIV in cats as a model for HIV.

Authors:  Mary Jo Burkhard; Gregg A Dean
Journal:  Curr HIV Res       Date:  2003-01       Impact factor: 1.581

10.  Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques.

Authors:  A I Spira; P A Marx; B K Patterson; J Mahoney; R A Koup; S M Wolinsky; D D Ho
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  82 in total

Review 1.  Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice.

Authors:  Paul W Denton; J Victor Garcia
Journal:  Trends Microbiol       Date:  2012-04-12       Impact factor: 17.079

Review 2.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

3.  Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.

Authors:  Jiehua Zhou; C Preston Neff; Xiaoxuan Liu; Jane Zhang; Haitang Li; David D Smith; Piotr Swiderski; Tawfik Aboellail; Yuanyu Huang; Quan Du; Zicai Liang; Ling Peng; Ramesh Akkina; John J Rossi
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

4.  The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.

Authors:  Kieran Seay; Nazanin Khajoueinejad; Jian Hua Zheng; Patrick Kiser; Christina Ochsenbauer; John C Kappes; Betsy Herold; Harris Goldstein
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

Review 5.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

6.  RAG2-/- gamma(c)-/- mice transplanted with CD34+ cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus.

Authors:  Ursula Hofer; Stefan Baenziger; Mathias Heikenwalder; Erika Schlaepfer; Nadine Gehre; Stephan Regenass; Thomas Brunner; Roberto F Speck
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

7.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.

Authors:  Lee Adam Wheeler; Radiana Trifonova; Vladimir Vrbanac; Emre Basar; Shannon McKernan; Zhan Xu; Edward Seung; Maud Deruaz; Tim Dudek; Jon Ivar Einarsson; Linda Yang; Todd M Allen; Andrew D Luster; Andrew M Tager; Derek M Dykxhoorn; Judy Lieberman
Journal:  J Clin Invest       Date:  2011-05-16       Impact factor: 14.808

8.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 9.  Novel humanized murine models for HIV research.

Authors:  Paul W Denton; J Victor Garcia
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

Review 10.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.